Boundless Bio Inc
NASDAQ:BOLD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
W
|
Woosu AMS Co Ltd
KOSDAQ:066590
|
KR |
|
S
|
Silver Bullet Data Services Group PLC
LSE:SBDS
|
UK |
|
Nettlinx Ltd
BSE:511658
|
IN |
|
N
|
Namchow Holdings Co Ltd
TWSE:1702
|
TW |
|
Maris Tech Ltd
NASDAQ:MTEK
|
IL |
|
West Fraser Timber Co Ltd
TSX:WFG
|
CA |
|
Terrain Minerals Ltd
ASX:TMX
|
AU |
|
Nava Limited
NSE:NAVA
|
IN |
|
O
|
Optus Pharmaceutical Co Ltd
KOSDAQ:131030
|
KR |
|
B
|
Bougainville Copper Ltd
ASX:BOC
|
PG |
|
Protagonist Therapeutics Inc
NASDAQ:PTGX
|
US |
|
Novocure Ltd
NASDAQ:NVCR
|
JE |
|
E
|
Evolve Education Group Ltd
ASX:EVO
|
NZ |
|
Shanghai AJ Group Co Ltd
SSE:600643
|
CN |
|
Cleanaway Co Ltd
TWSE:8422
|
TW |
|
P
|
PS International Group Ltd
NASDAQ:PSIG
|
HK |
|
N
|
Narrowstep Inc
OTC:NRWS
|
US |
|
Birla Cable Ltd
NSE:BIRLACABLE
|
IN |
|
BBMG Corp
SSE:601992
|
CN |
|
S
|
SVC Industries Ltd
BSE:524488
|
IN |
|
Abacus Group
ASX:ABG
|
AU |
|
Mgi Digital Technology SA
OTC:FRIIF
|
FR |
|
LG Corp
KRX:003550
|
KR |
|
Everest Kanto Cylinder Ltd
NSE:EKC
|
IN |
Boundless Bio Inc
Research & Development
Boundless Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Boundless Bio Inc
NASDAQ:BOLD
|
Research & Development
-$44.8m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Boundless Bio Inc
Glance View
Boundless Bio Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 71 full-time employees. The company went IPO on 2024-03-28. Boundless Bio, Inc. is a clinical-stage oncology company, which is engaged in cancer therapeutics that addresses the unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Using its proprietary Spyglass platform, it identifies targets essential for ecDNA functionality in oncogene amplified cancer cells, then designs and develops small molecule drugs called ecDNA-directed therapeutic candidates (ecDTx) to inhibit those targets. Its lead ecDTx, BBI-355, is an oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells. BBI-355 demonstrated CHK1 inhibition and tumor regressions in ecDNA-enabled preclinical cancer models and is being studied in a first-in-human, Phase I/II clinical trial in patients with oncogene amplified cancers. Its second ecDTx, BBI-825, is an oral, selective inhibitor of ribonucleotide reductase, which is essential for ecDNA assembly and repair in cancer cells.
See Also
What is Boundless Bio Inc's Research & Development?
Research & Development
-44.8m
USD
Based on the financial report for Dec 31, 2025, Boundless Bio Inc's Research & Development amounts to -44.8m USD.
What is Boundless Bio Inc's Research & Development growth rate?
Research & Development CAGR 3Y
-6%
Over the last year, the Research & Development growth was 19%. The average annual Research & Development growth rates for Boundless Bio Inc have been -6% over the past three years .
